Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806033 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
A Phase 2 study of B Cell Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06806033: Recruiting Phase 2 study of B Cell Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche.
NCT06806033 is a Phase 2 study of B Cell Non-Hodgkin's Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06806033, a Phase 2 study of B Cell Non-Hodgkin's Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Oxaliplatin
- DRUG Gemcitabine
Study Locations (20)
California
- Community Cancer Institute (CCI) - Clovis
- Providence Medical Foundation - Fullerton
- Los Angeles Cancer Network - Glendale
- Valkyrie Clinical Trials - Los Angeles
- Zuckerberg San Francisco General Hospital - San Francisco
- The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente - Torrance
Florida
- North Florida/ South Georgia VA Medical Center - Gainesville
- Mount Sinai Comprehensive Cancer Center - Miami
- Orlando Health Cancer Institute - Orlando
New York
- New York Oncology Hematology, P.C. - Albany
- Hematology Oncology Associates of Central New York - East Syracuse
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Colorado
- Rocky Mountain Cancer Centers, LLP - Aurora
Idaho
- St Luke?s Cancer Institute - Boise
Illinois
- Cancer Care Specialists of Central Illinois - Swansea
Iowa
- Mission Blood and Cancer - MercyOne Cancer Center - Waukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
What NCT06806033 shows while recruiting
NCT06806033 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with B Cell Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT06806033 names 20 study sites across 12 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06806033 about?
NCT06806033 is a clinical study titled "A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma". This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid pr...
What is the current status of trial NCT06806033?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-03-05. Estimated completion is 2029-03-30.
What conditions does trial NCT06806033 study?
This clinical trial studies the following conditions: B Cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT06806033?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT06806033?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06806033 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B Cell Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06806033's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI